Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK V1180L |
| Therapy | Crizotinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK V1180L | lung non-small cell carcinoma | resistant | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, a human non-small cell lung cancer cell line harboring ALK V1180L in the context of EML4-ALK was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534). | 25228534 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25228534) | Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. | Full reference... |